SEC Form 4 · accession 0001562180-17-002237
Sage Therapeutics, Inc. · SAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael F Cola
Director
Period of report
Jun 7, 2017
Accepted (ET)
Jun 8, 2017 · 7:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597553
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $72.74 | Jun 7, 2017 | A | 14,000 | A | — | Jun 7, 2027 | Common Stock | 14,000 | 14,000 | D |
Explanation of responses
- F1The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan. The option will vest in full upon the earlier to occur of June 7, 2018 or the day immediately prior to the 2018 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date.